ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial (2023)
- Authors:
- USP affiliated authors: GIAVINA-BIANCHI JUNIOR, PEDRO FRANCISCO - FM ; KALIL FILHO, JORGE ELIAS - FM
- Unidade: FM
- DOI: 10.1016/j.jacig.2023.100140
- Subjects: CORONAVIRUS; COVID-19; PLACEBOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2023
- Source:
- Título: Journal of allergy and clinical immunology: global
- ISSN: 2772-8293
- Volume/Número/Paginação/Ano: v. 2, n. 4, article ID 100140, p, 2023
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
GIAVINA-BIANCHI JÚNIOR, Pedro Francisco et al. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial. Journal of allergy and clinical immunology: global, v. 2, n. 4, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58602. Acesso em: 09 abr. 2026. -
APA
Giavina-Bianchi Júnior, P. F., Cua, E., Risso, K., Mondain, V., Vissian, A., Joie, C., et al. (2023). ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial. Journal of allergy and clinical immunology: global, 2( 4). doi:10.1016/j.jacig.2023.100140 -
NLM
Giavina-Bianchi Júnior PF, Cua E, Risso K, Mondain V, Vissian A, Joie C, Pouletty P, Gineste P, Ehrlich HJ, Kalil Filho JE. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial [Internet]. Journal of allergy and clinical immunology: global. 2023 ; 2( 4):[citado 2026 abr. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58602 -
Vancouver
Giavina-Bianchi Júnior PF, Cua E, Risso K, Mondain V, Vissian A, Joie C, Pouletty P, Gineste P, Ehrlich HJ, Kalil Filho JE. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial [Internet]. Journal of allergy and clinical immunology: global. 2023 ; 2( 4):[citado 2026 abr. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58602 - Adults and children with anaphylaxis in the emergency room: why it is not recognized?
- Debate on drugs that may aggravate COVID-19. [Carta]
- Allergy To Betalactams In Brazil: Placebo Effect Or Misdiagnosis?
- Associated factors with sensitisation and allergy to latex
- New associations between HLA genotypes and asthma phenotypes
- Anaphylaxis to quinolones in mastocytosis: hypothesis on the mechanism
- Sensitisation by subcutaneous route is superior to intraperitoneal route in the induction of asthma by house dust mite in a murine model
- Increase of 10% in the Rate of Adverse Drug Reactions for Each Drug Administered in Hospitalized Patients
- Atopy Is Associated with Age at Asthma Onset in Elderly Patients
- Drug-Induced Anaphylaxis
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
